CSF2

CSF2 Full Name

colony stimulating factor 2 (granulocyte-macrophage)

CSF2 Introduction

CSF2 (colony stimulating factor 2), more commonly known as granulocyte-macrophage colony-stimulating factor (GM-CSF), is a pleiotropic cytokine that plays a central role in regulating hematopoiesis, innate immunity, and tissue homeostasis. Encoded by the CSF2 gene located on chromosome 5q31, GM-CSF is produced by a variety of cell types, including T lymphocytes, macrophages, endothelial cells, fibroblasts, and epithelial cells in response to inflammatory stimuli. Researchers investigating immune dysregulation, chronic inflammation, or impaired host defense frequently encounter CSF2 because of its broad influence on myeloid cell development and activation. Human GM-CSF is a glycoprotein consisting of 127 amino acids and functions through binding to the heterodimeric GM-CSF receptor, activating downstream JAK2/STAT5, MAPK, PI3K-AKT, and NF-κB signaling pathways. Beyond its established role in stimulating granulocyte and macrophage production, CSF2 has emerged as a critical regulator of immune cell communication, making it an important target in both immunology research and therapeutic development.

One of the most distinctive biological functions of CSF2 is its ability to coordinate immune responses while maintaining tissue-specific homeostasis, particularly within the lung. Studies in Csf2-deficient animal models have demonstrated that the absence of GM-CSF results in impaired alveolar macrophage maturation, defective surfactant clearance, and progressive accumulation of proteinaceous material within the alveoli. These findings established GM-CSF as an indispensable factor for pulmonary immune balance and normal respiratory function. In addition to supporting macrophage differentiation and survival, CSF2 enhances antigen presentation, promotes dendritic cell maturation, regulates neutrophil activity, and influences T-cell responses. Through these mechanisms, GM-CSF bridges innate and adaptive immunity, allowing the host to mount effective defenses against infections while coordinating inflammatory responses. However, excessive or prolonged CSF2 signaling can drive pathological inflammation, highlighting the importance of tightly controlled expression and receptor-mediated signaling.

Dysregulated CSF2 expression has been implicated in a wide spectrum of human diseases, making it a highly relevant biomarker and therapeutic target. Elevated GM-CSF activity contributes to chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and severe asthma, where excessive activation of myeloid cells amplifies tissue damage and disease progression. Conversely, neutralizing autoantibodies against GM-CSF are strongly associated with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder characterized by impaired surfactant clearance and increased susceptibility to opportunistic infections. Growing evidence also links CSF2 to cancer progression and metastasis. Recent studies have shown that epigenetic and post-transcriptional regulation of CSF2 can reshape the tumor microenvironment, promote recruitment of immunosuppressive myeloid populations, and facilitate tumor growth. For example, increased CSF2 expression in gastric cancer-associated stromal cells has been correlated with tumor recurrence and poor clinical outcomes. Furthermore, CSF2 and related colony-stimulating factors are increasingly recognized as contributors to bone metastasis, cancer-associated inflammation, and resistance to anti-tumor immunity. As a result, CSF2 remains an area of intense research interest for the development of next-generation immunotherapies, anti-inflammatory agents, and precision medicine strategies targeting immune-mediated diseases and cancer.

Alternate Names for CSF2

CSF2; colony stimulating factor 2 (granulocyte-macrophage); Csfgm; GMCSF; Gm-CSf; MGI-IGM; granulocyte-macrophage colony-stimulating factor; CSF; put. GM-CSF; colony-stimulating factor; granulocyte-macrophage colony stimulating factor 2;

• 1.Chen Y, et al.; Role of GM-CSF in lung balance and disease. Front Immunol. 2023, 14:1158859.
  2.Ataya A, et al.; The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review. Front Immunol. 2021, 12:752856.